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item EORTC QLQ-C30, its corresponding 13-item lung cancer 
supplement, and the EuroQol disease-generic questionnaire. 
Indirect costs of productivity loss were evaluated using the short 
form health and labor questionnaire, which includes work 
absences, reduced efficiency at work, and substitution for 
unpaid work. Time to deterioration (TTD) in HRQOL was 
calculated from time to randomization to first appearance of 
clinically significant change. TTD was analyzed using Cox 
proportional hazard models. The Embase and MEDLINE databases 
were systematically reviewed to obtain English language articles 
investigating patient-reported HRQOL after SABR for ES-NSCLC 
up to August 1, 2015. Review articles, meta-analyses and 
decision analyses were excluded. Relevant data regarding 
patient characteristics and study outcomes were abstracted and 
analyzed. 
Results:  In the ROSEL study, only TTD of global health status 
was significantly worse on univariable modeling for surgical 
patients compared to SABR (HR 0.19, p = 0.038). Indirect costing 
analysis revealed lower total productivity costs to society for 
SABR compared to surgery (€95 versus and €3,513, p = 0.044). 
Patients reported a lower total degree of hindrance in paid and 
unpaid work for SABR compared to surgery (mean hindrance 
scores for SABR: 1.9, for surgery: 6.0, p = 0.010). In the 
systematic review, nine out of 204 potential studies met all 
inclusion criteria and were analyzed. All studies were 
prospective in design. Overall SABR appeared to be well-
tolerated, in a mostly medically inoperable patient population. 
Clinically and statistically significant deteriorations in fatigue 
and dyspnea were individually reported in two studies. An 
isolated report found clinically and statistically significant 
improvements in emotional functioning over time. Deterioration 
in dyspnea and physical functioning were noted in other studies, 
but were neither statistically nor clinically significant. 
Conclusions:  SABR is an overall well-tolerated modality in 
patients with ES-NSCLC who either declined surgery or were 
unfit. Exploratory results in operable ES-NSCLC suggest that SABR 
may be better tolerated than surgery and incur indirect costing 
savings. Future clinical trials comparing SABR and surgery would 
benefit from the inclusion of HRQOL metrics in study design. 
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Purpose: In patients undergoing surgery for Stage I NSCLC, the 
delivery of neoadjuvant SABR has been proposed as a method of 
improving oncologic outcomes. A Phase II trial was launched to 
evaluate oncologic outcomes, pCR rates, and toxicity after SABR 
followed by surgical resection. The protocol mandated an 
interim safety analysis after completion of combined treatment 
in the first 10 patients. 
Methods and Materials: Operable patients with biopsy-proven 
T1T2N0 NSCLC were eligible. SABR was delivered using a risk-
adapted fractionation (54 Gy/3 fractions, 55/5 fractions or 60/8 
fractions, all with biologically effective dose > 100 Gy10), 
prescribed to the ~80% isodose line covering the planning target 
volume. Surgical resection was planned 10 weeks later, either 
lobectomy or sublobar resection, at a high-volume tertiary 
centre completing more than 200 lung cancer resections 
annually. Patients were imaged with dynamic FDG-PET CT and 
dynamic contrast enhanced CT before SABR and again before 
surgery. Toxicity was recorded using CTCAE version 4.0. 
Results: Twelve patients were enrolled between September 2014 
and September 2015. Two did not undergo surgery after SABR 
due to patient or surgeon preference; neither patient has 
developed toxicity or recurrence. For the 10 patients completing 
both treatments, median age was 70 (range 54-76), 60% had T1 
disease, and 60% had adenocarcinoma. Median FEV1 was 73% 
predicted (range 54-87%). Median time to surgery post-SABR was 
10.1 weeks (range 9.3-15.6 weeks). Surgery consisted of 
lobectomy (n = 8) or wedge resection (n = 2). Median follow up 
post-SABR was 6.3 months. After combined treatment, the rate 
of Grade 3-4 toxicity was 10% (one patient with pneumonia, atrial 
fibrillation, and respiratory failure [post-operative re-intubation 
due to mucus plugging], all resolved). Seven patients developed 
Grade 2 toxicities. Thirty- and 90-day mortality post-surgery 
were both 0%. 
Conclusions: Toxicity rates after SABR + surgical resection 
compare very favourably with reported rates in prospective 
studies of surgical resection alone (~48% Grade 3-5 toxicity after 
lobectomy [1] and ~30% after wedge resection [2]). Mature data 
on pCR rates and oncologic outcomes from this combined 
modality strategy are awaited. 
 
158 
TUMOUR RESPONSE TO STEREOTACTIC BODY RADIATION THERAPY 
(SBRT) AS PREDICTOR OF DISTANT FAILURE AND SURVIVAL 
OUTCOMES IN PATIENTS WITH STAGE I NON-SMALL CELL LUNG 
CANCER (NSCLC) 
Michael Tjong1, Ian Poon2, Salman Faruqi1, Joelle Helou1, Liying 
Zhang1, Patrick Cheung1, Darby Erler1 
1University of Toronto, Toronto, ON 
2Odette Cancer Centre, Toronto, ON 
 
Purpose: SBRT is an alternative treatment to surgery for Stage I 
NSCLC. Intriguingly, NSCLC lesions post-SBRT rarely exhibit a 
complete response locally and yet yield excellent local control 
of around 95%. The degree of treatment response seems to have 
little effect on in current practice. This study investigated 
tumour response post-SBRT as a clinical outcomes predictor in 
Stage I NSCLC patients. 
Methods: Survival outcomes of 233 patients were reviewed 
retrospectively from Sunnybrook Electronic Patient Record. 
Tumour sizes were collected from radiologist’s measurements 
based on CT-Scan pre and post-SBRT within 6, 12, and 18 months 
intervals. Each patient’s maximum response within 18 months 
was calculated and grouped using RECIST 1.1 methodology: 
complete response (CR), partial response (PR), stable disease 
(SD), and progressive disease (PD). 
Results: The median age of study population was 77.5 years. 
Median follow up duration was 25 months. Local control (LC), 
overall survival (OS), and non-local control (NLC) for all patients 
at two years were: 92.5, 74.6, and 68.0% respectively. Of 
patients with available pre and post-SBRT tumour sizes (n = 188), 
11 (5.9%), 92 (48.9%), 79 (42.0%), and six (3.2%) patients were 
categorized CR, PR, SD, and PD respectively using RECIST 1.1 
methodology. LC were: CR (100%), PR (94.0%), SD (89.7%), and 
PD (66.7%) respectively after two years. OS were: CR (80.0%), PR 
(80.8%), SD (72.0%), and PD (44.4%) respectively. NLC were: CR 
(100%), PR (66.4%), SD (62.5%) and PD (16.7%) respectively. 
There is a statistically significant difference in NLC between 
groups (p = 0.0009). 
Conclusions: Stage I NSCLC patients with a lesser response post-
SBRT are at higher risk of developing non-local recurrences. 
These patients may benefit from closer follow up and adjuvant 
treatment post-SBRT. 
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